December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Studies get to root of dandruff, reveal new causes, cures for ailment
July 1st 2002New Orleans - When it comes to understanding dandruff, two top researchers at Procter & Gamble are successfully getting to the root of the nasty scalp condition that affects more than half of the global population. Innovative research in P&G's lab has yielded some surprising new data about a type of fungus that grows on the human scalp. The study findings point to new causes of dandruff and lay the groundwork for new cures.
Shoe-related CD sometimes hard to size up
June 1st 2002Maui, Hawaii - Shoe-related allergic contact dermatitis is commonlyoverlooked in the differential diagnosis of foot dermatitis, mainly becausepatients are not patch tested, according to James S. Taylor, M.D. at theSkin Disease Education Foundation's 26th Hawaii Dermatology Seminar.
UV light relieves itch of multiple etiologies
June 1st 2002Mechanism action UVB treatment isinactivation of pruritogenic substancesNewOrleans - UV light therapy has been used to treat a variety of pruriticconditions, although there is a lack of definitive data regarding the efficacyof the therapeutic modality in some of the disorders for which it has beentried, Henry W. Lim, M.D., said at the annual meeting of the American Academyof Dermatology.
Pimecrolimus, tacrolimus keep in check pediatric AD
June 1st 2002New Orleans - New long-term data with the topical immunomodulator tacrolimus(Protopic) and the skin-selective inflammatory cytokine inhibitor pimecrolimus(Elidel) demonstrate efficacy as maintenance therapies in the treatmentof atopic dermatitis in children. Data with pimecrolimus show safety andefficacy for as long as 26 weeks in infants as young as three months, LawrenceEichenfield, M.D., said at the annual meeting of the American Academy ofDermatology.
Studies further condemn UVA reputation
May 1st 2002New Orleans - The role of UVA radiation in generating a number of diseases is now much better understood, Robert Bissonnette, M.D., said at the annual meeting of the American Academy of Dermatology. "If you go back 10 years, we knew a lot about UVB but little about UVA. Now, we know that it can cause skin cancer in animals," he said.